- Home
- QTTB
as 10-07-2025 12:47pm EST
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 23.3M | IPO Year: | N/A |
| Target Price: | $12.17 | AVG Volume (30 days): | 65.7K |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.34 - $53.17 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Q32 Bio Inc. Common Stock (QTTB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kalowski Lee | QTTB | CFO and President | Aug 26 '25 | Sell | $1.80 | 4,240 | $7,636.24 | 49,010 | |
| Violette Shelia M. | QTTB | Chief Scientific Officer | Aug 26 '25 | Sell | $1.80 | 2,990 | $5,384.99 | 58,384 | |
| Morrison Jodie Pope | QTTB | CEO | Aug 26 '25 | Sell | $1.80 | 10,494 | $18,899.69 | 121,506 |
Latest Q32 Bio Inc. Common Stock News
QTTB Breaking Stock News: Dive into QTTB Ticker-Specific Updates for Smart Investing
PR Newswire
3 months ago
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
TipRanks
3 months ago
Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary
GlobeNewswire
3 months ago
OXB completes acquisition of remaining stake in US subsidiary
PR Newswire
5 months ago
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
PR Newswire
5 months ago
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
PR Newswire
6 months ago
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
PR Newswire
7 months ago
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
PR Newswire
7 months ago
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
Compare QTTB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QTTB Q32 Bio Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.